In Vivo Assessment of Astrocyte Reactivity in Patients with Progressive Supranuclear Palsy.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
21 May 2024
21 May 2024
Historique:
revised:
12
03
2024
received:
21
12
2023
accepted:
16
04
2024
medline:
21
5
2024
pubmed:
21
5
2024
entrez:
21
5
2024
Statut:
aheadofprint
Résumé
Although astrocytic pathology is a pathological hallmark of progressive supranuclear palsy (PSP), its pathophysiological role remains unclear. This study aimed to assess astrocyte reactivity in vivo in patients with PSP. Furthermore, we investigated alterations in brain lactate levels and their relationship with astrocyte reactivity. We included 30 patients with PSP-Richardson syndrome and 30 healthy controls; in patients, tau deposition was confirmed through The levels of myo-inositol and plasma glial fibrillary acidic protein were significantly higher in patients than those in healthy controls (p < 0.05); these increases were significantly associated with PSP rating scale and cognitive function scores (p < 0.05). The lactate level was high in patients, and correlated significantly with high myo-inositol levels. Histological analysis of the anterior cingulate cortex in patients revealed reactive astrocytes, despite mild tau deposition, and no marked synaptic loss. We discovered high levels of astrocyte biomarkers in patients with PSP, suggesting astrocyte reactivity. The association between myo-inositol and lactate levels suggests a link between reactive astrocytes and brain energy metabolism changes. Our results indicate that astrocyte reactivity in the anterior cingulate cortex precedes pronounced tau pathology and neurodegenerative processes in that region, and affects brain function in PSP. ANN NEUROL 2024.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP19H01041
Organisme : Japan Society for the Promotion of Science
ID : JP21K18268
Organisme : The Collaborative Research Project of the Brain Research Institute, Niigata University
Organisme : Japan Agency for Medical Research and Development
ID : JP19dm0207072
Organisme : Japan Agency for Medical Research and Development
ID : JP21zf0127004
Organisme : Japan Agency for Medical Research and Development
ID : JP22dk0207055
Organisme : Japan Agency for Medical Research and Development
ID : JP22dk0207063
Informations de copyright
© 2024 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Verkhratsky A, Nedergaard M. Physiology of astroglia. Physiol Rev 2018;98:239–389.
Escartin C, Galea E, Lakatos A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci 2021;24:312–325.
Lawrence JM, Schardien K, Wigdahl B, Nonnemacher MR. Roles of neuropathology‐associated reactive astrocytes: a systematic review. Acta Neuropathol Commun 2023;11:42.
Dickson DW, Rademakers R, Hutton ML. Progressive supranuclear palsy: pathology and genetics. Brain Pathol 2007;17:74–82.
Whitwell JL, Höglinger GU, Antonini A, et al. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be? Mov Disord 2017;32:955–971.
Chatterjee P, Vermunt L, Gordon BA, et al. Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: associations with Aβ‐PET, neurodegeneration, and cognition. Alzheimers Dement 2023;19:2790–2804.
Baiardi S, Quadalti C, Mammana A, et al. Diagnostic value of plasma p‐tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther 2022;14:153.
Spotorno N, Najac C, Stomrud E, et al. Astrocytic function is associated with both amyloid‐β and tau pathology in non‐demented APOE ϵ4 carriers. Brain Commun 2022;4:fcac135.
Hirata K, Matsuoka K, Tagai K, et al. Altered brain energy metabolism related to astrocytes in Alzheimer's disease. Ann Neurol 2024;95:104–115.
Heckova E, Dal‐Bianco A, Strasser B, et al. Extensive brain pathologic alterations detected with 7.0‐T MR spectroscopic imaging associated with disability in multiple sclerosis. Radiology 2022;303:141–150.
Brand A, Richter‐Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15:289–298.
Klietz M, Mahmoudi N, Maudsley AA, et al. Whole‐brain magnetic resonance spectroscopy reveals distinct alterations in neurometabolic profile in progressive supranuclear palsy. Mov Disord 2023;38:1503–1514.
Varrone A, Pagani M, Salvatore E, et al. Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease. Eur J Nucl Med Mol Imaging 2007;34:1071–1081.
Stevens FL, Hurley RA, Taber KH. Anterior cingulate cortex: unique role in cognition and emotion. J Neuropsychiatry Clin Neurosci 2011;23:121–125.
Gerstenecker A, Mast B, Duff K, et al. Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy. Arch Clin Neuropsychol 2013;28:104–113.
Beard E, Lengacher S, Dias S, et al. Astrocytes as key regulators of brain energy metabolism: new therapeutic perspectives. Front Physiol 2021;12:825816.
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 2017;32:853–864.
Tagai K, Ono M, Kubota M, et al. High‐contrast in vivo imaging of tau pathologies in Alzheimer's and non‐Alzheimer's disease tauopathies. Neuron 2021;109:42–58.e8.
Starkstein SE, Fedoroff JP, Price TR, et al. Apathy following cerebrovascular lesions. Stroke 1993;24:1625–1630.
Mekle R, Mlynárik V, Gambarota G, et al. MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med 2009;61:1279–1285.
Simpson R, Devenyi GA, Jezzard P, et al. Advanced processing and simulation of MRS data using the FID appliance (FID‐A)‐an open source. MATLAB‐based toolkit Magn Reson Med 2017;77:23–33.
Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672–679.
Wilson M, Andronesi O, Barker PB, et al. Methodological consensus on clinical proton MRS of the brain: review and recommendations. Magn Reson Med 2019;82:527–550.
Takado Y, Takuwa H, Sampei K, et al. MRS‐measured glutamate versus GABA reflects excitatory versus inhibitory neural activities in awake mice. J Cereb Blood Flow Metab 2022;42:197–212.
Harris AD, Puts NA, Edden RA. Tissue correction for GABA‐edited MRS: considerations of voxel composition, tissue segmentation, and tissue relaxations. J Magn Reson Imaging 2015;42:1431–1440.
Panchal H, Sollmann N, Pasternak O, et al. Neuro‐metabolite changes in a single season of university ice hockey using magnetic resonance spectroscopy. Front Neurol 2018;9:616.
Endo H, Tagai K, Ono M, et al. A machine learning‐based approach to discrimination of tauopathies using [(18) F]PM‐PBB3 PET images. Mov Disord 2022;37:2236–2246.
Tatebe H, Kasai T, Ohmichi T, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case‐control studies including patients with Alzheimer's disease and down syndrome. Mol Neurodegener 2017;12:63.
Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease‐associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389–404.
Braak H, Braak E. Neuropathological stageing of Alzheimer‐related changes. Acta Neuropathol 1991;82:239–259.
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 2017;89:88–100.
Saito Y, Ruberu NN, Sawabe M, et al. Staging of argyrophilic grains: an age‐associated tauopathy. J Neuropathol Exp Neurol 2004;63:911–918.
Ito J, Shimizu H, Ohta K, et al. Amyotrophic lateral sclerosis with Pallidonigroluysian degeneration: a clinicopathological study. Ann Neurol 2020;87:302–312.
Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol 2020;140:99–119.
Sjöstedt E, Zhong W, Fagerberg L, et al. An atlas of the protein‐coding genes in the human, pig, and mouse brain. Science 2020;367;eaay5947.
Chouliaras L, Thomas A, Malpetti M, et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2022;93:651–658.
Togo T, Dickson DW. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. Acta Neuropathol 2002;104:398–402.
Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid‐β but not tau pathology in Alzheimer's disease. Brain 2021;144:3505–3516.
Tu W, Ma Z, Ma Y, et al. Suppressing anterior cingulate cortex modulates default mode network and behavior in awake rats. Cereb Cortex 2021;31:312–323.
Blin J, Baron JC, Dubois B, et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990;47:747–752.
Shah D, Gsell W, Wahis J, et al. Astrocyte calcium dysfunction causes early network hyperactivity in Alzheimer's disease. Cell Rep 2022;40:111280.
Boumezbeur F, Mason GF, de Graaf RA, et al. Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J Cereb Blood Flow Metab 2010;30:211–221.
Targa Dias Anastacio H, Matosin N, Ooi L. Neuronal hyperexcitability in Alzheimer's disease: what are the drivers behind this aberrant phenotype? Transl. Psychiatry 2022;12:257.
Pioro EP, Majors AW, Mitsumoto H, et al. 1H‐MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology 1999;53:71–79.
Ollivier M, Soto JS, Linker KE, et al. Crym‐positive striatal astrocytes gate perseverative behaviour. Nature 2024;627:358–366.
Ratai EM, Annamalai L, Burdo T, et al. Brain creatine elevation and N‐Acetylaspartate reduction indicates neuronal dysfunction in the setting of enhanced glial energy metabolism in a macaque model of neuroAIDS. Magn Reson Med 2011;66:625–634.
Aerts MB, Esselink RA, Bloem BR, Verbeek MM. Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Mov Disord 2011;26:169–173.
Stamelou M, Pilatus U, Reuss A, et al. In vivo evidence for cerebral depletion in high‐energy phosphates in progressive supranuclear palsy. J Cereb Blood Flow Metab 2009;29:861–870.
Liguori C, Stefani A, Sancesario G, et al. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2015;86:655–659.
Rowland LM, Pradhan S, Korenic S, et al. Elevated brain lactate in schizophrenia: a 7 T magnetic resonance spectroscopy study. Transl Psychiatry 2016;6:e967.
Hagihara H, Shoji H, Hattori S, et al. Large‐scale animal model study uncovers altered brain pH and lactate levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive impairment. Elife 2024;12:RP89376.
Proia P, Di Liegro CM, Schiera G, et al. Lactate as a metabolite and a regulator in the central nervous system. Int J Mol Sci 2016;17:1450.
Albers DS, Beal MF. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem Int 2002;40:559–564.
Horvat A, Muhič M, Smolič T, et al. Ca(2+) as the prime trigger of aerobic glycolysis in astrocytes. Cell Calcium 2021;95:102368.
Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A 1994;91:10625–10629.
Zhang M, Cheng X, Dang R, et al. Lactate deficit in an Alzheimer disease mouse model: the relationship with neuronal damage. J Neuropathol Exp Neurol 2018;77:1163–1176.
Monsorno K, Buckinx A, Paolicelli RC. Microglial metabolic flexibility: emerging roles for lactate. Trends Endocrinol Metab. 2022;33:186–195.
Szablewski L. Brain glucose transporters: role in pathogenesis and potential targets for the treatment of Alzheimer's disease. Int J Mol Sci 2021;22:8142.
Simpson IA, Chundu KR, Davies‐Hill T, et al. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 1994;35:546–551.
Mullins R, Reiter D, Kapogiannis D. Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain. Ann Clin Transl Neurol 2018;5:262–272.
Yang C, Wang H, Shao M, et al. Brain‐type glycogen phosphorylase (PYGB) in the pathologies of diseases: a systematic review. Cells 2024;13:289.
Boxer AL, Geschwind MD, Belfor N, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006;63:81–86.